Doubts have been expressed by FDA advisers over the benefits of using carvedilol in patients who have had a recent MI.
The panel are due to consider GlaxoSmithKline’s request to expand the use of carvedilol, which is already approved for treating hypertension and mild to severe heart failure.
The company claim that trials showed that carvedilol cut mortality by 23% when used to treat MI
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!